Pulsenmore Receives FDA De Novo Marketing Authorization for Home-Use Prenatal Ultrasound, Pioneering a New Era of Prenatal Care in the U.S.
PR Newswire —
RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for the Pulsenmore ES, a home-use prenatal ultrasound platform...